{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:58:28Z","timestamp":1791316708778,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.105918","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:49:55Z","timestamp":1766177395000},"page":"105918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-270X","authenticated-orcid":false,"given":"A.","family":"Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4175-8055","authenticated-orcid":false,"given":"Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-6767","authenticated-orcid":false,"given":"F.","family":"Cappuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hallwachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-7819","authenticated-orcid":false,"given":"J.","family":"Bolleddula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sarholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9855-7429","authenticated-orcid":false,"given":"T.","family":"Grombacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Otte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2755-6597","authenticated-orcid":false,"given":"I.","family":"Gounaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-3364","authenticated-orcid":false,"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.105918_bib62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/cancers17020255","article-title":"Recent advances in the clinical translation of small-cell lung cancer therapeutics","volume":"17","author":"Das","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105918_bib1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105918_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105918_bib3","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105918_bib4","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.chest.2018.07.029","article-title":"Characteristics and outcomes of small cell lung cancer detected by CT screening","volume":"154","author":"Thomas","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105918_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","article-title":"Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group","volume":"10","author":"Roth","year":"1992","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105918_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/curroncol28010036","article-title":"Real world analysis of small cell lung cancer patients: prognostic factors and treatment outcomes","volume":"28","author":"Moser","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.esmoop.2025.105918_bib7","series-title":"Lung Cancer: Treatment and Research","first-page":"301","article-title":"Small cell lung cancer","author":"Bernhardt","year":"2016"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105918_bib8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.esmoop.2025.105918_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105918_bib10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14737140.2017.1372198","article-title":"Second-line treatments of small-cell lung cancers","volume":"17","author":"Baize","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105918_bib11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.21037\/tlcr-20-362","article-title":"Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined","volume":"9","author":"Choua\u00efd","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105918_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241272957","article-title":"Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis","volume":"16","author":"Gomez-Randulfe","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2025.105918_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932105","article-title":"Lurbinectedin in small cell lung cancer","volume":"12","author":"Manzo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2025.105918_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2025.105918_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107448","article-title":"Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval \u226530 days and without central nervous metastases","volume":"188","author":"Peters","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105918_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep18999","article-title":"Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients","volume":"6","author":"Horita","year":"2016","journal-title":"Sci Rep"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105918_bib17","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105918_bib19","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217313","article-title":"ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer","volume":"15","author":"Schultz","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.esmoop.2025.105918_bib20","article-title":"Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of lurbinectedin in this setting","volume":"39","author":"Badin","year":"2024","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105918_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105918_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.lungcan.2020.03.024","article-title":"Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) \u2013 a decision-making analysis amongst European lung cancer experts","volume":"146","author":"Fr\u00fch","year":"2020","journal-title":"Lung Cancer"},{"issue":"22","key":"10.1016\/j.esmoop.2025.105918_bib23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105918_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105918_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105918_bib28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"346","key":"10.1016\/j.esmoop.2025.105918_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6282","article-title":"Small cell lung cancer: time to revisit DNA-damaging chemotherapy","volume":"8","author":"Thomas","year":"2016","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105918_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105918_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/2767-9764.CRC-22-0168","article-title":"Replication stress defines distinct molecular subtypes across cancers","volume":"2","author":"Takahashi","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105918_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105918_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"issue":"7267","key":"10.1016\/j.esmoop.2025.105918_bib34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105918_bib35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2025.105918_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918786658","article-title":"Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies","volume":"10","author":"Minchom","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105918_bib37","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.105918_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000086183","article-title":"Mechanisms of drug resistance in cancer chemotherapy","volume":"14","author":"Luqmani","year":"2005","journal-title":"Med Princ Pract"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105918_bib39","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105918_bib40","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105918_bib41","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105918_bib42","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105918_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105918_bib44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"43","key":"10.1016\/j.esmoop.2025.105918_bib45","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105918_bib46","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"7563","key":"10.1016\/j.esmoop.2025.105918_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105918_bib48","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","article-title":"Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial","volume":"9","author":"Takahashi","year":"2023","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105918_bib49","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1007\/s12325-021-01909-1","article-title":"Advances in treatment of recurrent small cell lung cancer (SCLC): insights for optimizing patient outcomes from an expert roundtable discussion","volume":"38","author":"Das","year":"2021","journal-title":"Adv Ther"},{"issue":"34","key":"10.1016\/j.esmoop.2025.105918_bib50","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O\u2019Brien","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105918_bib53","doi-asserted-by":"crossref","first-page":"TPS8613","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8613","article-title":"A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator\u2019s choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)","volume":"41","author":"Besse","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105918_bib55","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"Suppl 3","key":"10.1016\/j.esmoop.2025.105918_bib56","article-title":"104TiP Phase Ib\/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies","volume":"9","author":"Paz-Ares","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105918_bib57","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor tuvusertib (M1774) induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105918_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165615","article-title":"The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy","volume":"8","author":"Vendetti","year":"2023","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105918_bib59","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105918_bib60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105918_bib61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:33:19Z","timestamp":1773934399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2059702925017880"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105918","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105918"}}